Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medigen Biotechnology Corp.

www.medigen.com.tw

Latest From Inimex Pharmaceuticals Inc.

New CEO at Inimex Pharmaceuticals

The privately held biopharmaceutical company Inimex Pharmaceuticals has appointed Dr Michael Abrams president and CEO. In 1996, Dr Abrams led the establishment of AnorMED and served as the company's president and CEO until 2006. AnorMED was acquired by Genzyme for $580 million in 2006.

Companies

Start-Up Previews (11/04)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Biotechs Battle Bacteria, features profiles of AureoGen Biosciences, Biovertis, Inimex Pharmaceuticals and Prolysis. Plus these Start-Ups across Health Care: Afmedica, Intercept Pharmaceuticals and MAP Pharmaceuticals.

Inimex Pharmaceuticals Inc.

The basis for Inimex's pipeline was born a few years ago when company founders teamed up to investigate small cationic peptides as antimicrobials for the Canadian Bacterial Diseases Network. They found that some cationic peptides didn't kill bacteria, but had the ability to prevent or treat infection in animal models. The trio led a team to concentrate on a unique expression profile that activated innate response without stimulating inflammation, and that research forms the foundation of the company's current portfolio of compounds that selectively boost immunity.
BioPharmaceutical

Biotechs Battle Bacteria

The rise in bacterial resistance has prompted a plethora of creative approaches to developing antibiotics. These range from finding completely novel targets to harnessing the body's own immune system to fight bacteria. And although biotechs have had the anti-bacterials space to themselves for the last few years, as more programs reach proof of concept, some Big Pharma may be showing signs of renewed interest.
BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Gene Therapy, Cell Therapy
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
    • Generic Drugs
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Hepatic (Liver)
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Taiwan
  • Parent & Subsidiaries
  • Medigen Biotechnology Corp.
  • Senior Management
  • Stanley Chang, Chmn. & CEO
    Bill Ou, CFO
    Conrad Lai, PhD, VP, New Drug Dev.
  • Contact Info
  • Medigen Biotechnology Corp.
    Phone: (886) 2-7736-1234
    14F., No.3, Park St.
    Nangang Dist.
    Taipei, 11503
    Taiwan
Advertisement
Advertisement
UsernamePublicRestriction

Register